{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:16:19Z","timestamp":1779297379507,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jval.2022.05.011","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T01:38:38Z","timestamp":1660181918000},"page":"1977-1985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure"],"prefix":"10.1016","volume":"25","author":[{"given":"Andreas","family":"Nikolaou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cosmina","family":"Hogea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yevgeniy","family":"Samyshkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric M.","family":"Maiese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Sansbury","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cid-Ruzafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritika","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2022.05.011_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"10.1016\/j.jval.2022.05.011_bib3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.4065\/79.7.867","article-title":"Clinical course of patients with relapsed multiple myeloma","volume":"79","author":"Kumar","year":"2004","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.jval.2022.05.011_bib4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","article-title":"Management of multiple myeloma in the relapsed\/refractory patient","volume":"2017","author":"Sonneveld","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"7","key":"10.1016\/j.jval.2022.05.011_bib5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/17474086.2016.1195254","article-title":"Real-world treatment patterns and associated progression-free survival in relapsed\/refractory multiple myeloma among US community oncology practices","volume":"9","author":"Jagannath","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"20","key":"10.1016\/j.jval.2022.05.011_bib6","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jval.2022.05.011_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jval.2022.05.011_bib10","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/pds.3927","article-title":"Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model","volume":"25","author":"Cid-Ruzafa","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.jval.2022.05.011_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.6004\/jnccn.2018.0002","article-title":"NCCN guidelines insights: multiple myeloma, version 3.2018","volume":"16","author":"Kumar","year":"2018","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"14","key":"10.1016\/j.jval.2022.05.011_bib12","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.jval.2022.05.011_bib13","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/17474086.2020.1800451","article-title":"Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Bruno","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"10.1016\/j.jval.2022.05.011_bib14","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.clml.2018.06.018","article-title":"Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study","volume":"18","author":"Mohty","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"25","key":"10.1016\/j.jval.2022.05.011_bib15","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.jval.2022.05.011_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.jval.2022.05.011_bib17","unstructured":"Centers for Disease Control and Prevention. Death rates by 10-year age groups: United States and each state, 2007. https:\/\/www.cdc.gov\/nchs\/data\/dvs\/MortFinal2007_Worktable23r.pdf. Accessed November 11, 2020."},{"issue":"2","key":"10.1016\/j.jval.2022.05.011_bib18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jval.2022.05.011_bib19","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/ejh.13317","article-title":"Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: a network meta-analysis","volume":"103","author":"Xu","year":"2019","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jval.2022.05.011_bib20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/jnci\/djy073","article-title":"Association between autologous stem cell transplant and survival among Californians with multiple myeloma","volume":"111","author":"Rosenberg","year":"2019","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.jval.2022.05.011_bib21","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ajh.25098","article-title":"Treatment patterns and clinical outcomes in high-risk newly diagnosed multiple myeloma patients carrying the 17p deletion: an observational multi-center retrospective study","volume":"93","author":"Cohen","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jval.2022.05.011_bib22","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.clml.2018.04.003","article-title":"Real-world outcomes of multiple myeloma: retrospective analysis of the Czech registry of monoclonal gammopathies","volume":"18","author":"Hajek","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.jval.2022.05.011_bib23","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/leu.2017.256","article-title":"Outcomes of maintenance therapy\u00a0with lenalidomide or bortezomib in multiple myeloma in the setting\u00a0of early autologous stem cell transplantation","volume":"32","author":"Chakraborty","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.jval.2022.05.011_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00019053-200725010-00002","article-title":"Rates and probabilities in economic modelling: transformation, translation and appropriate application","volume":"25","author":"Fleurence","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.jval.2022.05.011_bib26","first-page":"1","article-title":"Solving differential equations in R: package deSolve","volume":"33","author":"Soetaert","year":"2010","journal-title":"J\u00a0Stat Softw"},{"issue":"4","key":"10.1016\/j.jval.2022.05.011_bib27","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/HS9.0000000000000045","article-title":"Long-term outcomes in patients with multiple myeloma: a retrospective analysis of the Dutch population-based haematological registry for observational studies (PHAROS)","volume":"2","author":"Verelst","year":"2018","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.jval.2022.05.011_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00277-016-2889-2","article-title":"Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib","volume":"96","author":"Berenson","year":"2017","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.jval.2022.05.011_bib29","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jval.2022.05.011_bib30","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jval.2022.05.011_bib31","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2016003905","article-title":"Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed\/refractory patients","volume":"1","author":"Botta","year":"2017","journal-title":"Blood Adv"},{"issue":"10192","key":"10.1016\/j.jval.2022.05.011_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (Cassiopeia): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jval.2022.05.011_bib33","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2217\/fon-2020-0970","article-title":"Estimate of multiple myeloma patients by line of therapy in the US: population-level projections 2020-2025","volume":"17","author":"Kanas","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.jval.2022.05.011_bib35","author":"Cocito"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522019994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522019994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:27:55Z","timestamp":1761096475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522019994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1098301522019994"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.05.011","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Epidemiology Model for Estimating the Numbers of US Patients With Multiple Myeloma by Line of Therapy and Treatment Exposure","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}